Axsome races for Alzheimer's agitation approval
A successful phase III study for the US-based biotech firm puts it neck and neck with Lundbeck, a Danish pharma firm that also has a candidate for the Alzheimer’s related disease under development.
by albert rønning-andersson, translated by daniel pedersen
US-based biotech company Axsome Therapeutics has now come so far in the development of its candidate that soon, it may be able to reasonably announce that it has found a treatment for Alzheimer’s agitation, a disease suffered by 40–70% of all Alzheimer’s patients with no treatment options today.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
